Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Operations

v3.2.0.727
Condensed Consolidated Statement of Operations - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Revenue        
Medical devices $ 1,048 $ 690 $ 2,033 $ 1,217
Engineering services 1,066 507 1,770 1,042
Total revenue 2,114 1,197 3,803 2,259
Cost of revenue        
Cost of medical devices 970 502 1,768 832
Cost of engineering services 642 650 1,130 902
Total cost of revenue 1,612 1,152 2,898 1,734
Gross profit 502 45 905 525
Operating expenses        
Sales and marketing 2,523 1,849 4,374 3,380
Research and development 1,742 699 2,725 1,468
General and administrative 1,872 1,809 3,534 3,880
Total operating expenses 6,137 4,357 10,633 8,728
Loss from operations (5,635) (4,312) (9,728) (8,203)
Other income (expense)        
Interest expense $ (3) (3) $ (6) (430)
Gain (loss) on warrant liability   60,458   (16,979)
Interest income $ 3 2 $ 7 3
Other expense, net (10) (17) (33) (29)
Total other income (expense), net (10) 60,440 (32) (17,435)
Net income (loss) $ (5,645) $ 56,128 $ (9,760) $ (25,638)
Basic net income (loss) per share $ (0.06) $ 0.72 $ (0.10) $ (0.35)
Weighted-average shares used in computing basic per share amounts 102,094,158 78,497,558 101,944,359 72,688,073
Diluted net income (loss) per share $ (0.06) $ (0.05) $ (0.10) $ (0.35)
Weighted-average shares used in computing diluted per share amounts 102,094,158 94,772,411 101,944,359 72,688,073